Nufarm's Seed Technologies Review Unlikely to Realize Full Potential -- Market Talk

Dow Jones
2025/05/22
 

2309 GMT - Nufarm's decision to review its Seed Technologies business isn't likely to deliver a good result for shareholders, reckons Jefferies. Nufarm says all options are on the table for Seed Technologies in the UBS-led review. Nufarm has grappled with low fish-oil pricing in recent months, which led it to tell investors that it won't achieve a target of A$100 million of omega-3 revenue in FY 2025. Analyst Ramoun Lazar says the review "is likely to result in subscale outcomes for shareholders, given constrained near-term AquaTerra economics due to poor pricing and suboptimal production cost profile." Jefferies downgrades Nufarm to "underperform," from "hold," and cuts its price target by 55%, to A$1.96/share. Nufarm ended Wednesday at A$2.81. (david.winning@wsj.com; @dwinningWSJ)

 

(END) Dow Jones Newswires

May 21, 2025 19:09 ET (23:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10